Results 241 to 250 of about 115,987 (377)

Associations of Albuminuria and Metabolic Syndrome Traits With Fracture Risk in Patients With Type 2 Diabetes: A Population‐Based Cohort Study

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT Background Type 2 diabetes is associated with an increased risk of fragility fractures. While obesity may protect against fractures, individuals with type 2 diabetes often exhibit other metabolic syndrome (MetS) traits and albuminuria. We evaluated their roles and synergistic implications on incident fractures, stratified by obesity status ...
Xi Xiong, David T. W. Lui, Chengsheng Ju, Xiaodong Liu, Li Wei, Manju Chandran, Carlos K. H. Wong   +6 more
wiley   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis. [PDF]

Int J Cardiol Heart Vasc
Holt MF, Michelsen AE, Flø A, Russell K, Beitnes JO, Kløve SF, Hodt A, Gullestad L, Aukrust P, Gude E, Broch K, Ueland T.   +11 more
europepmc   +1 more source

The relationship between carotid intima-media thickness and serum secreted frizzled-related protein-4 and dipeptidyl peptidase-4 in diabetic patients with cardiovascular diseases

, 2019
Abdurrahman Şenyiğit, Hafize Uzun, İlhami Gültepe, Dildar Konukoğlu   +3 more
openalex   +2 more sources

Bioactive Peptides from Germinated Soybean with Anti-Diabetic Potential by Inhibition of Dipeptidyl Peptidase-IV, α-Amylase, and α-Glucosidase Enzymes [PDF]

, 2018
Marcela González-Montoya, Blanca Hernández‐Ledesma, Rosalva Mora‐Escobedo, Cristina Martı́nez-Villaluenga   +3 more
openalex   +1 more source

Exertional heat stress and intestinal barrier injury: Does chronic disease add fuel to the fire?

Experimental Physiology, EarlyView.
Oliver R. Gibson, Zachary J. McKenna
wiley   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings, Serbülent Ünsal, Mathieu Rappas, Matthew Barnes, Maria Waldhoer, Ben Holland, Martin Culka   +6 more
wiley   +1 more source

Novel Methods for the Quantification of Dipeptidyl Peptidase 3 (DPP3) Concentration and Activity in Human Blood Samples [PDF]

, 2018
Linda Rehfeld, Eugenia Funk, Shalinee Jha, Peter Macheroux, Olle Melander, Andreas Bergmann   +5 more
openalex   +1 more source

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Circulation, 2017
M. Nauck, J. Meier, M. Cavender, Mirna Abd El Aziz, D. Drucker   +4 more
semanticscholar   +1 more source

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Vildagliptin (VDG) is a dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor used for type 2 diabetes (T2DM) treatment. Viewing to improve VDG treatment, a population pharmacokinetic (popPK) model was built to describe drug plasma, free liver and muscle concentrations determined by microdialysis in healthy and diabetic animals following 50 mg/kg i.v ...
Bruna Bernar Dias, Laura Ben Olivo, Bibiana Verlindo de Araújo   +2 more
wiley   +1 more source

In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]

J Endocr Soc
Galsgaard KD, Abba V, Kuhre RE, Holst JJ, Hartmann B.   +4 more
europepmc   +1 more source